Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Barinthus Biotherapeutics plc - American Depositary Shares (NQ: BRNS ) 1.180 -0.020 (-1.66%) Streaming Delayed Price Updated: 3:51 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Barinthus Biotherapeutics plc - American Depositary Shares Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease September 24, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results August 08, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors August 01, 2024 From Sagimet Biosciences Inc. Via GlobeNewswire Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections June 12, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B June 06, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024 May 22, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments May 13, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer May 01, 2024 Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections April 18, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments March 20, 2024 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones January 05, 2024 From Barinthus Biotherapeutics Via GlobeNewswire New partnership aims to advance vaccine against MERS coronavirus December 21, 2023 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD November 09, 2023 From Barinthus Biotherapeutics Via GlobeNewswire Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments November 09, 2023 From Barinthus Biotherapeutics Via GlobeNewswire Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting® November 09, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.